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Abstract
Background: Gastrin-releasing peptide is a member of the bombesin family of peptides. Its cognate receptor, gastrin releasing
peptide receptor (GRPR), is widely expressed in cancers of the lung, pancreas and ovaries. Gastrin releasing peptide (GRP) is an
autocrine growth factor in small cell lung cancer, which has very poor patient outcomes. High affinity antagonist peptides have
been developed for in vivo cancer imaging. In this report we decorated pegylated liposomes with a GRPR antagonist peptide and
studied its interaction with, and accumulation within, lung cancer cells.
Results: An N-terminally cysteine modified GRPR antagonist (termed cystabn) was synthesised and shown to inhibit cell growth in
vitro. Cystabn was used to prepare a targeted 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-
2000] (DSPE-PEG2000) lipid conjugate that was formulated into liposomes. The liposomes displayed desirable colloidal proper-
ties and good stability under storage conditions. Flow cytometric and microscopic studies showed that fluorescently labelled
cystabn-decorated liposomes accumulated more extensively in GRPR over-expressing cells than matched liposomes that contained
no cystabn targeting motif.
Conclusion: The use of GRPR antagonistic peptides for nanoparticle targeting has potential for enhancing drug accumulation in
resistant cancer cells.
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Introduction
Small-cell lung cancer (SCLC) accounts for approximately one
in five lung cancer diagnoses. In spite of global efforts to
reduce tobacco smoking in recent decades, the incidence of
smoking-associated cancers such as SCLC remains high with
more than 142,000 deaths from lung cancer estimated in the
United States for 2019 [1]. Approximately 80% of the world's
1.1 billion smokers live in low- and middle-income countries,
where access to state of the art healthcare and diagnostic tech-
nologies is limited [2]. Alarmingly, the average life expectancy
of an untreated SCLC patient is less than four months due
to the high likelihood of diagnosis at the metastatic stage. With
intensive chemo- and radiotherapy the median survival
extends to only 14–18 months meaning new therapeutic ap-
proaches for targeted drug delivery to SCLC are desperately
needed.
SCLC belongs to a class known as neuroendocrine tumours in
which malignant cells secrete hormones and growth factors – a
trait inherited from the neuroendocrine cells of the bronchial
epithelium that are transformed and give rise to the early SCLC
tumours. Of the hormones known to be secreted by SCLC cells,
gastrin-releasing peptide (GRP), is the most widely studied.
GRP is the human homologue of the amphibian peptide,
bombesin, and plays a role in embryonic development and adult
repair of bronchial epithelia [3]. The GRP receptor, hereafter
termed GRPR, is a G-protein-coupled receptor and member of
the bombesin (BB) receptor family: BB1 receptor is activated
by neuromedin B (NMB); BB2 (also called GRPR) is activated
by GRP; the BB3 receptor shares only 50% homology with
BB1 and BB2 and is an orphan receptor with an unidentified
endogenous ligand.
The expression of bombesin-related peptides and the BB recep-
tors by SCLC cell lines and primary tumours have been widely
studied for the past three decades [3-6]. GRP and NMB secre-
tion by SCLC is known to cause an autocrine growth loop that
drives tumour growth. Therefore, a number of experimental
therapeutics or imaging agents targeted at the GRP-GRPR inter-
action, including anti-GRP antibodies and GRPR peptide antag-
onists have been developed. These agents have demonstrated
antitumour responses in a number of preclinical models of
pancreatic cancer [7] and imaging of breast [8], pancreatic [9]
and glioma [10] tumours.
The use of GRPR antagonists is motivated by their inability to
cause downstream cell growth effects, but is counter-balanced
by a greatly reduced rate of receptor internalisation. Nonethe-
less, a number of reports have illustrated that GRP/bombesin-
based antagonists display superior in vivo targeting capacity cf.
agonist peptides [11]. It is therefore reasonable to exploit the
enhanced targeting capacity of the antagonist peptides for en-
hanced targeting of SCLC. Indeed, we postulate that high-
affinity binding of antagonist peptides to SCLC cell surface
GRPR would be expected to increase the local accumulation of
the liposomes in the cell surface, thus increasing the probability
of drug accumulation in the target cells, without activating
GRPR signalling. For example, by increasing the fraction of
liposomes that are membrane-bound through GRPR binding cf.
non-targeted liposomes, which exchange rapidly between the
free and cell surface-bound state, would indirectly increase the
relative intracellular accumulation. Access to the intracellular
compartment would be achieved by constitutive plasma mem-
brane endocytosis (e.g., pinocytosis), resulting in membrane
internalisation, endosome formation and trafficking through the
endo-lysosomal system.
Nanomedicines to improve cancer therapy have been widely
studied and have resulted in a number of approved therapies
such as Doxil® in the 1990s and the recent approval of
Onivyde® [12]. In the lung cancer field, cisplatin formulated as
a pegylated liposomal formulation (Lipoplatin®) has delivered
comparable antitumour response against non-small cell lung
cancer tumours with reduced side effects when delivered in
combination with paclitaxel compared to when cisplatin and
paclitaxel solutions are used in combination [13]. In preclinical
studies, improved therapeutic responses have been achieved by
adopting an active targeting approach. Typically, this involves
the incorporation of a surface-bound moiety that selectively
binds to a cognate receptor/protein on the tumour cell surface,
leading to accumulation of nanocarriers in the tumour. A diver-
sity of targeting ligands has been explored, including anti-
bodies, proteins, peptides and aptamers. Targeted nanoparticles
such as HER2-targeted MM-302 [14], transferrin receptor-
targeted CALAA-01 [15], and prostate-specific membrane
antigen (PSMA)-targeted BIND-014 [16] have reached the
clinic but detailed information about the clinical advantage of
using targeted platforms is still forthcoming. In this study we
explored whether surface engraftment of a GRPR antagonist
peptide could be used to target GRPR expressing lung cancer
cells for the purposes of enhanced liposome delivery to lung
cancer.
Results and Discussion
GRPR as a target in lung cancer
The functionality of GRPR in SCLC cells was confirmed by
Fura-2 studies in which NCI-H345 or NCI-H82 SCLC cell
models were exposed to a dose-range of the canonical GRPR
agonist peptide, Tyr4-Bn. A dose-dependent increase in intra-
cellular calcium release was observed for NCI-H345 but not the
GRPR deficient SCLC line, NCI-H82 (Figure 1a,b), as previ-
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Figure 1: GRPR functionality in lung cancer cells. (A) Exemplar fluorescence trace from H345 cells loaded with Ca2+ reporter dye, Fura-2 AM before
injection of GRPR agonist, Tyr4-Bn. Baseline fluorescence was monitored for 30 s before peptide injection. (B) Escalating concentrations of Tyr4-Bn
were injected into H345 or H82 cells and the Fura-2 AM fluorescence emission monitored over 200 s. Peak Fura-2 ratios at 340/380 nm were plotted
against agonist concentration. Data are mean ± SD. H345 cells were cultured over 5 days in selenite-insulin-transferrin (SIT) serum-free medium in
the presence of escalating concentrations of Tyr4-Bn (C) or cystabn (D) before cell growth quantification by MTS assay. Similarly, (E, F) show MTS
growth data for H82 cells in the presence of Tyr4-Bn (E) or cystabn (F). Error bars are SD.
ously reported [17,18]. The physiological role of GRPR
includes the stimulation of a mitogenic response after receptor
internalisation [19]. SCLC growth as a result of stimulation by
nanoparticle targeting ligands is highly undesirable. We there-
fore sought to explore the use of GRPR antagonist peptides on
the liposomal carriers. Here, we exploited a peptide derived
Beilstein J. Nanotechnol. 2019, 10, 2553–2562.
2556
from the work of Mansi et al. who showed that the radiola-
belled antagonist peptide, 111In-DO3A-CH2CO-G-aminoben-
zoyl-ᴅ-Phe-Q-W-A-V-G-H-Sta-Leu-NH2 increased by 3.5-fold
the relative tumour accumulation of radiolabel compared to the
agonist peptide, 111In-DO3A-CH2CO-G-aminobenzoyl-Q-W-
A-V-G-H-L-M-NH2 [20,21]. This report reinforced the concept
that the use of GRPR antagonist peptides was strongly prefer-
able to the use of agonist peptides which have the potential to
fuel tumour growth. The use of antagonists in preference to
agonists is not, however, accepted by all. Different groups,
using different agonist/antagonist peptide pairs as well as differ-
ent imaging probes and visualisation approaches, have reached
different conclusions about which approach should be used
[22,23]. Based upon preferable in vitro and in vivo properties
reported by others we based our work on the statine (Sta)-based
antagonist peptide, ᴅ-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-
NH2.
The published peptide structure was modified to bear an N ter-
minal ʟ-cysteine residue, which enables subsequent attachment
to a functionalised lipid carrier. The peptide, hereafter termed
cystabn, was prepared by fluorenylmethoxycarbonyl (Fmoc)
solid-phase peptide synthesis and characterised by HPLC and
mass spectrometry (data not shown). To confirm the persistent
functionality of the peptide after cysteine addition, NCI-H345
cells were exposed to escalating concentration of Tyr4-Bn and
cystabn in serum-free conditions. As expected, Tyr4-Bn resulted
in a scalable increase (p < 0.05) in cell number as judged by
MTS assay (Figure 1c). In contrast, exposure to cystabn,
reduced cell proliferation over a 5 day period (Figure 1d), thus
confirming that the addition of an N terminal cysteine did not
interfere with GRPR binding. Exposure of NCI-H82 cells to the
Tyr4-Bn agonist (Figure 1e) and cystabn antagonist peptide
(Figure 1f) caused no change in cell growth.
These cell proliferation studies were performed in serum-free
conditions in line with previous studies [24,25] for two prin-
ciple reasons. Firstly, the removal of serum from the culture
medium depletes bovine bombesin-like peptides that could
otherwise stimulate cell growth. Secondly, the presence of
serum proteases could rapidly reduce the integrity of the
peptides, as demonstrated for other bombesin-related peptides
that displayed mouse and human serum half-lives measured in
the tens of hours [26]. The specificity of Tyr4-Bn and cystabn
activity was confirmed in GRPR depleted NCI-H82 cells. In
contrast to results from NCI-H345 cells, the addition of Tyr4-
Bn to NCI-H82 caused no noticeable increase in cell prolifera-
tion and cystabn effected no reduction in proliferation. This
demonstrated that cystabn functionally targeted GRPR
expressing cells in a specific manner – a key feature of a
targeting ligand to enable high tumour localisation.
Formulation of a GRP-targeted liposomal
carrier
Having validated GRPR as a functional target on the surface of
SCLC cells we next prepared a targeted liposomal carrier. The
presence of a single thiol group in the cystabn peptide affords
facile functionalisation of DSPE-PEG2000-maleimide thorough
thiol coupling chemistry. Successful conjugation of the
peptide was confirmed by MALDI–TOF mass spectrometry
(Figure 2a,b). The most abundant mass peak of DSPE-PEG2000-
cystabn (calculated mass: 4137.41 Da, assuming perfect
monodispersity of the PEG2000 group) was observed at 4188 Da
(Figure 2a) and was separated from surrounding peaks by
44 Da, which represents the mass of a single ethylene glycol
unit (Figure 2b).
Figure 2: Mass spectrometry characterisation of cystabn-lipid conju-
gate. MALDI–TOF mass spectra of crude DSPE-PEG2000-cystabn
conjugate (A) and purified, post-dialysis, DSPE-PEG2000-cystabn
conjugate (B).
Liposomal formulations were developed to incorporate DSPE-
PEG2000-cystabn or control DOPE-PEG2000 (see below
Table 2, in section Materials). Liposomes without targeting
cystabn peptide (control-lipo) contained 5 mol % DOPE-
PEG2000, whereas targeted formulations (target-lipo) were
loaded with 3 mol % of targeting DSPE-PEG2000-cystabn
conjugate with the total mass of PEG-lipid made up to 5% with
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2557
Figure 3: Colloidal stability of liposomes. Control and target liposomes were exposed to PBS (A,C) or 10% FBS in PBS (B,D) at three temperatures
for 24/72 h then analysed by DLS. Data shown are mean ± SD, n = 3.
DOPE-PEG2000. The formulations were prepared using the
thin-film technique to yield small and monodisperse vesicles as
judged by dynamic light scattering (DLS) analysis (Table 1).
Table 1: Colloidal properties of control- and target-lipo formulations.a
control-lipo target-lipo (3 mol %
cystabn conjugate)
Z-Ave (d.nm) 101 ± 2.1 90 ± 0.6
PDI 0.058 ± 0.007 0.050 ± 0.020
zeta potential (mV) −1.64 ± 2.13 −2.15 ± 0.2
aData shown are mean ± SD, n = 3 independent experiments.
The colloidal properties of both liposomal formulations were
highly similar in terms of size, polydispersity and zeta potential
and consistent with those reported for other pegylated lipo-
somes by others [27]. The vesicles were colloidally stable in
PBS over 72 h at temperatures of 4, 25 and 37 °C with no sig-
nificant changes in size, PDI or zeta potential observed
(Figure 3a,b). It was noted that the diameter of both liposome
formulations was larger than the 50 nm pore diameter of the ter-
minal extrusion membrane. This is likely due to the deforma-
tion of the vesicles under pressure during extrusion and subse-
quent expansion after emergence from the pore.
Commercial realisation of targeted nanomedicines is contin-
gent upon the development of platforms that are sufficiently
resistant to aggregation in body fluids such as blood. The
stability of control and targeted liposomes was examined after
exposure to 10% heat-inactivated FBS for 24 or 72 h at differ-
ent temperatures (Figure 3c,d). There were noticeable in-
creased in liposome size and PDI as a function of both incuba-
tion time and temperature. For example, the control-lipo vesi-
cles increased to 125 nm diameter after 24 or 72 h incubation at
37 °C. We noted a transition from a unimodal size distribution
of liposomes in PBS buffer to a multimodal size distribution
after extended incubation with 10% FBS. This caused sharp in-
creases in the PDI of both formulations with increases in size
and polydispersity (PDI) being greater for the target-lipo vesi-
cles.
The emergence of particle populations with different sizes is not
unexpected considering that FBS represents a complex, concen-
trated cocktail of polydisperse proteins of different sizes [27].
Indeed, the surface properties of various nanoparticles have
been shown to change dramatically in the presence of plasma or
serum [28] with the establishment of an adsorbed protein
corona around the nanoparticle. It is now widely accepted that
the particle protein corona presents a new biomolecular inter-
face that underpins the dynamic interactions of nanosystems
and their biological targets. The presentation of a high affinity
GRPR antagonist peptide on the liposomal surface is expected
to maintain liposomal cell-binding affinity by virtue of its high
affinity for the receptor. Although, steric blockade of the
targeting motif is possible due to the dynamic exchange events
association with the evolution of the hard and soft corona, even
on pegylated liposomes.
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Cell binding and uptake of GRPR-targeted
liposomes
The targeting capacity of cystabn-decorated liposomes was ex-
amined using two different approaches. To examine this, we
exploited a GRPR overexpression construct transfected into the
widely used, adherent non-SCLC cell line A549. This model
grows more rapidly than SCLC cells and its adherent pheno-
type allows for easier manipulation. First, quantification of cell-
uptake was judged by flow cytometry analysis of A549-GRPR
cells exposed to fluorescently tagged target-lipo (FL-Target-
lipo) or tagged control-lipo (FL-Control-lipo) formulations. Pre-
liminary studies using FL-Target-lipo including 1 mol %
targeting lipid showed marginal increases in relative cellular
accumulation (data not shown). To overcome this, the density
of targeting lipid was increased to 3 mol %. To examine for
active internalisation and intracellular accumulation of lipo-
somes at the endocytosis permissive temperature of 37 °C, we
subtracted the median fluorescence intensity (MFI) attributable
to cell-surface adsorption of liposomes at 4 °C, to yield a
“normalised cell MFI” at each time point and for each formula-
tion.
For non-targeted FL-Control-lipo, there was a modest increase
in normalised fluorescence over time (blue bars, Figure 4a). In
contrast, the fluorescence of FL-Target-lipo increased over time
(red bars, Figure 4a). Drawing comparison between the control
and targeted liposome groups, it was clear to see that at 15 min,
fluorescence was no greater in cells treated with FL-Target-lipo
compared to FL-Control-lipo. However, at 60 min and beyond
cell fluorescence was greater (p < 0.05) in cells treated with
target-lipo.
We next confirmed the flow cytometric results using fluores-
cence microscopy. Following 5 min exposure to either control
(Figure 4b) or target-liposomes (Figure 4c), A549-GRPR cells
displayed greater cellular fluorescence signals in the FL-Target-
lipo group. Cells exposed to FL-Control-lipo displayed a diffuse
cell membrane-like staining with few green fluorescent puncta.
Whereas, the target-lipo exposed cells displayed many more
fluorescent puncta as well as a widespread increase in cellular
fluorescence. Our observations here indicate that GRPR
targeting with cystabn peptide increases cell uptake of lipo-
somes, most likely through receptor-mediated uptake.
Taken together the flow cytometry and microscopy data demon-
strate that, using a fluorescently labelled model liposomal
carrier, the relative increase in cell uptake afforded by cystabn
functionalisation is modest but significant. To put our data into
context, approximately two-fold enhanced delivery of an oligo-
nucleotide-bombesin [3,7-14] conjugate was observed by Ming
et al. [29]. Using a similar approach to ours, Accardo et al.
Figure 4: GRPR targeting with cystabn increases cell accumulation of
liposomes. (A) A549-GRPR cells were exposed to 1 μg/mL of control
or target liposomes for 15–180 min before washing and analysis of
liposomal 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine
(DHPE)-fluorescein intensity by flow cytometry. Fold-change median
fluorescence intensity (MFI) was determined by correcting for the
background MFI from cells exposed for matched time periods on ice.
Data shown are mean ± SD, n = 3. A549-GRPR cells were exposed to
1 µg/mL of control (B) or target (C) liposomes (green) for 5 min,
washed, fixed and nuclei labelled with Hoechst (blue).
studied liposomal delivery of doxorubicin into PC-3 prostate
cells using a modified bombesin targeting peptide [30]. The
authors showed a reduction in mouse PC-3 xenograft size com-
pared to non-targeted doxorubicin liposomes and saline control,
consistent with tumour accumulation of the delivery system. In
summary, an increase in SCLC cellular accumulation of a lipo-
somal drug cargo would be beneficial for therapy, especially
considering the chemotherapeutic resistance profile that is often
displayed by clinical SCLC [31].
Future studies on cystabn-targeted liposomal carriers will exam-
ine the uptake and trafficking of these nanocarriers, particularly
with regards to their efficiency of carrying chemotherapeutic
agents into the cell. Poor intracellular accumulation of nanocar-
riers can be improved through targeted and triggered drug
release, for example through the incorporation of temperature-
sensitive [32] or light-sensitive lipids [33]. These approaches
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have shown promise in enhancing the cellular/tumoural accu-
mulation of chemotherapeutic agents in various models [34,35].
In spite of the enhanced cellular delivery shown here, the appli-
cation of GRPR targeting nanosized delivery systems to differ-
ent cancers should be considered carefully due to variability in
GRPR expression across malignant diseases. Published reports,
using techniques such as reverse-transcriptase polymerase chain
reaction (RT-PCR) and immunostaining, have shown that be-
tween 63–100% of prostate tumours are GRPR positive, while
SCLC tumours are more heterogeneous, with 29–85% of
tumours expressing GRPR [36]. This demonstrates that GRPR
expression is not a universal marker of SCLC or any other
tumour and that future development of GRPR-targeted thera-
peutics would require patient stratification according to the
expression status.
Conclusion
This report demonstrates that the functionalisation of lipo-
somes with a GRPR antagonist peptide is sufficient to promote
the accumulation of liposomes within GRPR expressing cells
such as SCLC. Increased internalisation of drug-loaded GRPR
targeted liposomes in treatment-resistant tumours such as SCLC
could offer improved therapeutic outcomes.
Experimental
Materials
Fmoc-protected amino acids, piperazine, HCTU, HOBt, DMF
were all from AGTC (Hessle, UK). Rink Amide MBHA resin
was from Novabiochem (UK). HPLC solvents and all cell cul-
ture media were from Sigma-Aldrich (Poole, UK). Lipids were
from Avanti Polar Lipids (USA). Sources of other exceptional
items are mentioned in the text.
Calcium release assay
NCI-H345 and NCI-H82 cells were loaded with 2 µM Fura-
2AM (Thermo Fisher, UK) in Hank’s Balanced Salt Solution
(HBSS) loading buffer containing sulfinpyrazone at 37 °C for
40–60 minutes. Following loading, the buffer was replaced with
HBSS and allowed to warm to 37 °C in a Flexstation 3 micro-
plate reader (Molecular Devices). Fluorescence of Fura-2 was
recorded using dual excitation (340 and 380 nm) and emission
520 nm. Agonist was automatically injected using the Flexsta-
tion compound plate and tips at a specific time point. PMT
settings were medium and 3 reads performed per well. Data is
represented as 340/380 ratio using zero baseline for normalisa-
tion.
Cell proliferation assay
The proliferation of NCI-H345 and NCI-H82 cells in the pres-
ence or absence of Tyr4-Bn and cystabn was studied in sele-
nium–insulin–transferrin (SIT) medium comprising 30 nM so-
dium selenite, 5 µg/mL human insulin, 10 μg/mL human
transferrin and 2 mM ʟ-glutamine in RPMI-1640 media. The
cells were seeded in 96 well plates overnight at a density of
30,000 cells per well. The cells were then treated with 100 or
500 nM Tyr4-Bn or cystabn and for 5 days with peptide replen-
ishment at day 3. Cell proliferation was determined using the
CellTiter 96® AQueous One assay (Promega).
Peptide synthesis
Cystabn (Cys-ᴅ-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2)
was synthesized on the Rink Amide MBHA resin using Fmoc
chemistry. After initial deprotection of the resin with 2 × 5 min
5% piperazine in DMF, each coupling step involved addition to
1 equiv of resin, Fmoc-protected amino acid, HCTU, HOBt and
DIPEA (4:4:4:8 equiv) in 1.5 mL DMF. The mixture was incu-
bated for 30 min at RT with occasional gentle agitation then
washed with DMF (×3). This process was repeated to increase
the peptide yield. Successful Fmoc removal and coupling of
amino acids was confirmed with the Kaiser test. After success-
ful coupling and Fmoc deprotection of the N-terminal amino
acid, the resin was washed with DMF (3 × 5 mL, 1 min), then
DCM (3 × 5 mL, 5 min) and the resin dried under nitrogen then
stored in vacuo for 3–5 h. Simultaneous side chain deprotection
and peptide cleavage from the resin was achieved using TFA/
TIPS/EDT/H2O (94:2:2:2), performed at RT for 4 h. The
peptide was precipitated in diethyl ether overnight at −20 °C.
Precipitated peptide was harvested by centrifugation (3000 rpm,
10 min, 4 °C). Peptide precipitate was washed (×3 cold
diethyl ether) then dissolved in 10% aqueous acetic acid and
lyophilised to yield a white powder.
Peptide-PEG-lipid conjugate synthesis
One equivalent of DSPE-PEG2000-maleimide (6.8 μmol in
4 mL chloroform) was added to two equivalents of cystabn
(13.3 μmol in 2 mL methanol) and stirred for 24 h at RT under
nitrogen gas. After confirmation of successful conjugation by
MALDI–TOF mass spectrometry analysis the solvent was evap-
orated and the reaction mixture re-dissolved in milli-Q water.
Unreacted peptide was removed by dialysis against milli-Q
water at RT for three days (the water changed every 2 h then
left overnight) using 2 kDa cut-off benzoylated dialysis tubing
(SpectroPor, Spectrum Labs, New Brunswick, USA). The puri-
fied conjugate was lyophilised to a dry white powder.
Characterisation of peptides and conjugates
HPLC
Samples were analysed using a gradient elution method using
mobile phase A (H2O + 0.1% TFA) and B solution (acetonitrile
+ 0.1% TFA) on a Perkin Elmer HPLC system comprising of
binary solvent pump, autosampler, UV–vis detector and Peltier
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column oven. Mobile phases were membrane degassed using
Millipore vacuum filtration with a 0.2 µm filter. The gradient
profile was 0–5 min 5% B, 5–25 min 5–95% B and 5 min
5% B. Peptide samples (≈1 mg/mL in milli-Q water) were
eluted on a Phenomenex Luna® C18 (2) LC Column (5 µm,
100 Å, 150 × 4.6 mm, Phenomenex, UK). Conjugate analysis
was performed on a Hypersil™ BDS C8 LC Column (3 µm,
130 Å, 150 × 4.6 m, Thermo Scientific, UK). Samples of 10 µL
were injected and elution monitored at 280 nm.
MALDI–TOF
Peptide samples (2 mg/mL in 1:1 acetonitrile: milli-Q water +
0.1% TFA) were mixed with an equal volume of a saturated
solution of α-cyanohydroxycinnamic acid (Sigma) and 1 µL
spotted twice onto the same well of a clean MALDI sample
plate. Peptide-PEG2000-lipid conjugates were dissolved in
chloroform at 2 mg/mL and a 1:1 mixture prepared with satu-
rated methanolic solution of universal MALDI matrix (Sigma-
Aldrich, UK). Samples were analysed using linear ion detec-
tion mode on a SHIMADZU Axima-CFR MALDI–TOF.
Liposomal formulation
Lipids for each liposomal formulation were dissolved in chloro-
form and mixed in a round-bottomed flask (see Table 2, below).
The concentration of lipid-PEG-peptide conjugate solutions in
chloroform were determined by UV spectroscopy using the
molar extinction coefficient for the peptide tryptophan residue
(5560 AU/mmol/mL). A thin film was produced by slow
evaporation of the solvent under vacuum followed by one hour
under high vacuum to remove solvent traces. The film was
hydrated with PBS to a final lipid concentration of 10 mg/mL
then heated to 55 °C and vortexed extensively to produce
MLVs. Five cycles of freeze-thawing (dry ice-acetone followed
by heating to 55 °C) were performed to produce reduce the
lamellarity of the vesicles. Finally, lipid suspensions were
extruded (21×) through polycarbonate membranes of 200 nm,
100 nm and 50 nm pore sizes to produce a narrow size distribu-
tion of LUVs.
Characterization of liposomal formulations
Liposomes were characterized for size and zeta potential using
Zetasizer Nano ZS. For size measurements the liposomal
suspension was diluted 1:10 with PBS. For zeta potential mea-
surements, the liposomal suspension was diluted 1:10 with PBS
and transferred to a clean folded capillary cell (Malvern,
DTS1070).
Liposomal stability in PBS and 10% serum
An aliquot of the liposomal suspension was diluted 1:10 with
either PBS or 10% FBS in PBS and transferred to individual
microcentrifuge tubes. Samples were incubated at 4, 25 or















37 °C. After 0, 24 and 72 hours the samples were transferred to
cuvettes and measured for size and PDI as described above.
Cell culture and transfection
The adherent, non-small cell cancer cell line A549 was stably
transfected with a plasmid encoding HA epitope-tagged
human GRP receptor (3xHA-GRPR pcDNA3.1+ plasmid
#GRPR00TN00, UMR cDNA Resource Center, USA) using
FuGene 6 and selected using 750 μg/mL G418 over three
weeks. Cells were subsequently maintained in 100 μg/mL
G418.
Flow cytometry
A549-GRPR cells were washed with warm PBS and blocked
for 5 h in 0.2% BSA in RPMI-1640 medium. The cells were
dissociated using Versene and aliquoted at a concentration of
106 cells per mL in phenol-red free SFM. The samples were in-
cubated at 37 or 4 °C for 5 min before treating with Control-
lipo or Target-lipo (1 µg/mL total lipids concentration) for
15–180 min. After incubation at 37 °C, cells were transferred
onto ice and washed using 500 µL phenol red-free SFM. Sam-
ples were analysed on a Beckman Coulter CytoFlex flow
cytometer using exited using 488 nm laser and the emitted
wavelength acquired using 585/42 bandpass filter. After doublet
exclusion, 104 events/sample were acquired in the gated popula-
tion, and analysed using CytExpert software (v2.3, Beckman
Coulter, USA).
Fluorescence microscopy
Cells were seeded onto 16 mm coverslips, and incubated for
24 h. Cells were washed (×3) with PBS for 5 min at RT and
treated with 1 µg/mL (total lipid) of fluorescein-labelled control
or target liposomes for 5 min at 37 °C. Coverslips were washed
(×3) with PBS, fixed with 4% PFA (10 min at RT) and residual
PFA quenched by 50 mM NH4Cl (15 min, RT). The cells
washed with PBS (×3) for 5 min, permeabilised with
0.2% Triton X-100 (10 min). Nuclei were stained with Hoechst
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33258, 1 µg/mL in PBST) then mounted on glass slides using
Prolong Gold mounting medium (Invitrogen). The cells were
viewed under a widefield microscope (Zeiss AxioPlan 2ie) and
images taken using Axiovision software and analysed using Fiji
software.
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